Rubella

Researchers are evaluating the protective efficacy and safety of a recombinant herpes zoster vaccine called LZ901 in healthy adults aged 40 years and older. This phase 3, randomized, double-blind, placebo-controlled trial aims to protect participants against shingles caused by the varicella zoster virus. The vaccine contains a tetramer of VZV glycoprotein E combined with an aluminum hydroxide adjuvant known to enhance immune response and widely used in vaccines worldwide. Participants will receive two doses of either the LZ901 vaccine or a placebo (aluminum hydroxide adjuvant) injected into the upper arm on day 0 and day 29. Around 26,000 participants will be enrolled, including a subgroup of about 3,000 to assess the consistency of immune response across three vaccine batches and monitor persistence of immunity up to 36 months. The study includes four groups: treatment main, placebo main, treatment immunization, and placebo immunization groups. Participants will undergo up to 24 visits depending on their group, including on-site and in-person visits for screening, vaccination, and follow-up assessments. Researchers will monitor vaccine efficacy 30 days after full immunization, track adverse events from immediate to 12 months post-vaccination, and evaluate immune response through antibody tests at multiple time points. The study also explores the vaccine's impact on reducing the severity and occurrence of postherpetic neuralgia in adults 40 years and older.

Researchers are collecting clinical data and biological samples from patients with severe skin reactions caused by drugs. These conditions include Stevens-Johnson syndrome, Lyell syndrome (toxic epidermal necrolysis), acute generalized exanthematous pustulosis (AGEP), drug reaction with eosinophilia and systemic symptoms (DRESS), drug-induced immunoglobulin A (IgA) bullous dermatosis, generalized bullous fixed drug reactions, maculopapular exanthema, and erythema multiforme. The goal is to better understand the biological and genetic causes of these drug reactions through research. Participants will provide various samples beyond routine care, including a small skin biopsy (6 mm punch), blood samples (43 mL), blister fluid, oral and nasal mucous membrane swabs, skin swabs, and stool samples. These samples will be stored in a specialized biological resource platform to allow detailed immunological, biological, and genetic studies. This is an observational study without specific treatment interventions. During the study, patients will undergo collection of clinical information and the biological samples described. Researchers will monitor the implementation of this collection and use the data and samples to perform various laboratory studies to explore the mechanisms of adverse drug reactions affecting the skin. Participation involves consenting and providing samples as outlined, with no therapeutic procedures. The study began in September 2018 and is expected to continue until 2028.

Researchers are investigating the effects of measles vaccine (MV) and Bacille Calmette-Guérin vaccine (BCG) given to women of fertile age before pregnancy, and the impact of providing early measles vaccination to their children. The study aims to understand both measles-specific and general immune benefits in mothers and children, focusing on antibody responses, viral loads after yellow fever vaccination, and overall health outcomes. This is a phase 4 randomized, triple-blind trial conducted in Guinea-Bissau, exploring the novel concept that vaccinating mothers with live vaccines may enhance protection for their children. In this trial, 2400 non-pregnant, HIV-negative women aged 15 to 35 will be randomly assigned to receive either the measles vaccine, BCG vaccine, or a saline placebo. Their children, all receiving BCG at birth as per local recommendations, will be further randomized at 20 weeks of age to receive either an early measles vaccine or placebo. All children will then receive the standard measles and yellow fever vaccines at 9 months. The study will create six groups combining maternal and child vaccination schedules to compare outcomes. Participants will be followed through regular home visits and health center monitoring. Women will have blood samples taken before and after vaccination to measure antibody levels. Children will be closely monitored monthly and have blood samples taken at specified ages to assess immune responses and viral loads. The study tracks morbidity and mortality data for both mothers and children over time, using interviews, hospital records, and vaccination documentation. The trial will continue until 2027, assessing which vaccination schedules best support health and immunity.

This research aims to promote vaccine confidence and increase vaccination rates for the Human papillomavirus (HPV) vaccine among vulnerable and underserved youth aged 11 to 14. It focuses on addressing the suboptimal uptake of this strongly recommended vaccine by assessing a game-based educational approach. The study is a pilot randomized controlled trial designed to evaluate feasibility and preliminary effectiveness in improving vaccine intent and uptake. Participants are divided into two groups: one group receives a game-based intervention designed to educate and encourage HPV vaccination, while the other group receives usual care without any intervention. The study involves parent-child dyads, with children aged 11 to 14 who have not yet received the HPV vaccine. The intervention is delivered via a health game, and the study measures changes from before to after the intervention. During the study, researchers will track participation rates, retention, involvement, and satisfaction with the intervention. They will also measure parents' intent to vaccinate their children immediately after the intervention and two months later, alongside actual vaccination uptake. Assessments occur at enrollment, immediately post-intervention, and two months afterward. The total study duration includes follow-up to monitor these outcomes and collect participant feedback.

Researchers are investigating the spread and impact of multiple infectious diseases in Cambodia, a country facing challenges in disease surveillance and laboratory capacity. This nationwide study uses a One Health approach to better understand disease burden, transmission, and population immunity for a broad range of pathogens including zoonotic, vector-borne, vaccine-preventable, and neglected tropical diseases. The goal is to provide evidence that supports targeted and culturally appropriate public health interventions and to create a model that can be applied in similar low- and middle-income countries. The study will enroll about 10,000 participants aged 2 to 75 from urban and rural areas across Cambodia through a multi-stage population sampling method. Participants will complete standardized questionnaires covering demographics, health status, mobility, animal contact, and healthcare access. Blood samples will be collected for multiplex serology to detect antibodies against 57 priority pathogens. This observational study does not involve treatments but focuses on extensive data and sample collection to support research and policy development. Participants will be visited at home for blood sampling and questionnaire completion between December 2025 and April 2026. Researchers will measure the presence of antibodies to assess prior exposure to various pathogens. The study also includes building a biobank and curated datasets for long-term research use. Community engagement and collaboration with national stakeholders aim to facilitate the uptake of findings. The total participation period spans the inclusion period with no intervention, focusing on observation and data collection.

Researchers are evaluating the safety and immune response of an investigational vaccine called CVI-VZV-001 for preventing herpes zoster (shingles) in healthy adults aged 50 to 64 years. This Phase I, open-label study compares different doses of CVI-VZV-001 with an active control vaccine called Shingrix. The study aims to explore how well the vaccine is tolerated and how it stimulates the immune system. Participants will receive two intramuscular injections at the start of the study and eight weeks later. Four groups are involved: three different dose levels of CVI-VZV-001 (0.37 mL, 0.50 mL, and 0.75 mL) and one group receiving the Shingrix vaccine (0.50 mL). Each participant receives two doses during the study period. During the study, participants will be monitored closely for immediate reactions within 30 minutes after vaccination and for local and systemic side effects for six days after each vaccination. Unsolicited symptoms will be tracked up to four weeks after the second dose, with serious and medically attended adverse events monitored for up to 48 weeks. Researchers will assess immune responses before and after vaccinations, including at 4, 24, and 48 weeks post-second dose, using laboratory tests and physical exams to evaluate safety and immune activity.